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Histamine/gamma-aminobutyric acid (GABA) neurons of posterior hypothalamus send
wide projections to many brain areas and participate in stabilizing the wake state. Recent
research has suggested that GABA released from the histamine/GABA neurons acts on
extrasynaptic GABAA receptors and balances the excitatory effect of histamine. In the
current study, we show the presence of vesicular GABA transporter mRNA in a majority of
quantified hypothalamic histaminergic neurons, which suggest vesicular release of GABA.
As histamine/GABA neurons form conventional synapses infrequently, it is possible that
GABA released from these neurons diffuses to target areas by volume transmission and
acts on extrasynaptic GABA receptors. To investigate this hypothesis, mice lacking
extrasynaptic GABAA receptor d subunit (Gabrd KO) were used. A pharmacological
approach was employed to activate histamine/GABA neurons and induce histamine and
presumably, GABA, release. Control and Gabrd KO mice were treated with histamine
receptor 3 (Hrh3) inverse agonists ciproxifan and pitolisant, which block Hrh3
autoreceptors on histamine/GABA neurons and histamine-dependently promote
wakefulness. Low doses of ciproxifan (1 mg/kg) and pitolisant (5 mg/kg) reduced
locomotion in Gabrd KO, but not in WT mice. EEG recording showed that Gabrd KO
mice were also more sensitive to the wake-promoting effect of ciproxifan (3 mg/kg) than
control mice. Low frequency delta waves, associated with NREM sleep, were significantly
suppressed in Gabrd KO mice compared with the WT group. Ciproxifan-induced
wakefulness was blocked by histamine synthesis inhibitor a-fluoromethylhistidine
(aFMH). The findings indicate that both histamine and GABA, released from histamine/
GABA neurons, are involved in regulation of brain arousal states and d-containing subunit
GABAA receptors are involved in mediating GABA response.
Keywords: extrasynaptic GABAA receptor, GABAA d subunit, Gabrd KO mice, Electroencephalogram, histamine,
GABA, ciproxifan, pitolisantin.org May 2020 | Volume 11 | Article 5941
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Hypothalamic tuberomammillary histaminergic neurons form a
relatively small population of cells involved in the regulation of
wakefulness, energy homeostasis, appetite, reward, and cognition
(Brown et al., 2001; Haas and Panula, 2003; Panula and
Nuutinen, 2013). Release of neuronal histamine is strongly
correlated with the wake vigilant state and regulated by a
variety of sleep- and wake- promoting neuron systems (Brown
et al., 2001; Zant et al., 2012; Rozov et al., 2014; Saito et al., 2018).
Hypothalamic histaminergic neurons contain multiple other
neurotransmitters and peptides (Airaksinen et al., 1992; Sundvik
and Panula, 2012). GABA was reported to be present in all
(Airaksinen et al., 1992) or a majority (Trottier et al., 2002;
Sundvik and Panula, 2012; Yu et al., 2015) of histaminergic
neurons, depending on detection method used and species
studied. Co-existence of GABA and histamine in hypothalamic
neurons has been known for a long time (Takeda et al., 1984), but
the role of GABA has been poorly understood.
Although GABA could be released non-canonically via
vesicular monoamine transporter (Vmat2) (Tritsch et al.,
2012), in histaminergic cultured neurons, GABA is not co-
localized with either histamine or Vmat2 immunoreactivity
(Kukko-Lukjanov and Panula, 2003). The presence of vesicular
GABA transporter (Vgat) in histaminergic neurons [identified
by presence of histidine decarboxylase (Hdc)] is controversial:
while a co-localization study using transgenic reporter mice and
immunostaining shows that the majority of Hdc-positive cells
also contain Vgat (Yu et al., 2015), another in situ hybridization
and immunostaining study suggests that only 7% of Hdc
immunoreactive cells contain Vgat mRNA (Venner et al.,
2019). To clarify this controversy, we used double fluorescence
in situ hybridization (dFISH) and quantified the number of
histaminergic neurons expressing Gad67 and Vgat mRNA,
which encode GABA-synthesizing enzyme glutamic acid
decarboxylase 67 (Gad67) and Vgat.
Currently, it is assumed that GABA from histamine/GABA
neurons diffuses by volume transmission to many brain regions
and provides tonic inhibition by acting on extrasynaptic GABAA
receptors (Yu et al., 2015). It has been hypothesized that the
function of this tonic inhibition is to balance the strong
excitatory effects of histamine or to increase the spiking
precision and, therefore, information processing (Yu et al.,
2015; Scammell et al., 2019). Tonic inhibition provided by
extrasynaptic GABAA d receptors can regulate the firing mode
of thalamic neurons (Cope et al., 2005) and may destabilize
thalamocortical oscillations (Bright et al., 2007).
The fact that histamine/GABA neurons do not make
many conventional synaptic contacts and the recent
electrophysiological data suggest that GABA most likely acts
on various high-affinity extrasynaptic GABAA receptors (Takagi
et al., 1986; Yu et al., 2015). Although there are several types of
extrasynaptic GABAA receptors expressed in the brain, most of
them harbor the d subunit (Brickley and Mody, 2012). Therefore,
we used mice lacking GABAA d subunits (Gabrd KO) (Mihalek
et al., 1999) and pharmacologically manipulated the release of
GABA and histamine from the histamine/GABA neurons inFrontiers in Pharmacology | www.frontiersin.org 2order to test whether abolition of tonic GABAergic inhibition
modulates the responses to altered histamine/GABA release. We
blocked inhibitory Hrh3 autoreceptors on histamine/GABA
hypothalamic neurons, which increases transmitter release
from these neurons and produces sustained wakefulness
(Arrang et al., 1983; Ligneau et al., 1998; Ligneau et al., 2007;
Schwartz, 2011; Nieto-Alamilla et al., 2016).
We hypothesized that removal of Hrh3 negative feedback on
histamine/GABA neurons will induce release of both histamine and
GABA, which will lead to a hypervigilant phenotype in Gabrd KO
mice lacking the balancing extrasynaptic GABAA d receptors. We
used locomotor activity assay and electroencephalogram/
electromyogram (EEG/EMG) recording to assess the effects of
pharmacological treatments. To verify that wake-promoting effect
of the Hrh3 antagonist/inverse agonist ciproxifan was due to
enhanced histamine release, we pre-treated mice with a-
fluoromethylhistidine (aFMH), an irreversible inhibitor of Hdc
(Maeyama et al., 1982; Watanabe et al., 1990).METHODS
Animals
The principles of the Finnish Act on the Use of Animals for
Experimental Purposes were followed, and all protocols were
approved by the Animal Experiment Committee of the State
Provincial Office of Southern Finland. Animals were group-
housed in individually ventilated cages. Access to food pellets and
water was assured ad libitum. The condition of each mouse was
evaluated on a daily basis. Animal rooms were maintained on a 12–
12 h light–dark cycle (lights on at 6 a.m.). Temperature and
humidity were controlled at 20 ± 1°C and 50 ± 10%, respectively.
Seven 8- to 12-week-old C57BL/6J mice were used for dFISH.
In total 150 littermate Gabrd WT and KO female and male mice
(Mihalek et al., 1999) derived from heterozygous breedings were
used. One group of the mice was used for locomotor activity
assay after ciproxifan and then pitolisant treatment, another
group was used for locomotor activity assay after ciproxifan
treatment and EEG study. The washout period between the tests
was at least one week. The mice were 3 to 6 months old at the
start of locomotor activity assay and 6 to 7 months at the start of
EEG experiment.
Chemicals
Ciproxifan hydrochloride (AOB 33754; Aobious, Gloucester,
MA, USA) and pitolisant hydrochloride (AOB2752; Aobious,
Gloucester, MA, USA) were dissolved in saline. Drug doses
correspond to free bases of the compounds. Injections were
given intraperitoneally (i.p.) and the injection volume was 0.01
ml/g body weight.
Alpha-fluoromethylhistidine hydrochloride (aFMH) was a
kind gift from Dr. J. Kollonitch (Merck Sharp & Dohme,
Rahway, N.J., USA) and was also dissolved in saline. The drug
dose 50 mg/kg corresponds to salt of the compound.
Drugs used in the surgeries were lidocaine (10 mg/ml, Orion
Pharma, Finland), carprofen (50 mg/ml, Rimadyl, Pfizer, USA),
and buprenorphine (0.3 mg/ml, Temgesic, Reckitt Benckiser,May 2020 | Volume 11 | Article 594
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2.5%; Attane, Piramal Healthcare, Bethlehem, PA, USA).
Double Fluorescence In Situ Hybridization
Mice (n = 7) were transcardially perfused with 4% PFA as
described (Abdurakhmanova et al., 2017). Dissected brains
were cut on a cryostat, and 25-µm sections were collected on
glass slides. Every 10th section from −1.46 to −2.7 Bregma
anterior/posterior coordinates (Paxinos and Franklin, 2001)
was used for dFISH (n = 5 for Hdc/Gad67 and n = 4 for Hdc/
Vgat dFISH; 5–6 sections per animal).
Total RNA was extracted from mouse hypothalamus with
Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany) according to
manufacturer's protocol. RNA was used for reverse transcription
(SuperScript III reverse transcriptase kit) and cDNA synthesis.
Fragments of Hdc (position 1118–2212 NM_008230.6), Gad67
(position 1064–2046 NM_008077.4) and Vgat (position 866–1818
NM_009508.2) mRNA were amplified from cDNA (DyNAzyme II
polymerase kit, Thermo Scientific F-551). The PCR fragments were
extracted from 0.7% agarose gel with MinElute gel extraction kit
(Qiagen, Hilden, Germany) and cloned to pGEM-T Easy vector
(Promega A1360, Fitchburg, WI, USA). DH5a bacteria were
transformed with plasmid, and the insert was verified by
sequencing. RNA antisense probe for detecting Hdc was
synthesized from plasmid and labeled with either dinitrophenol
(DNP) or fluorescein isothiocyanate (FITC) and probes for
detecting Gad67 and Vgat were labeled with digoxigenin (DIG)
(RNA labeling kit; Roche, Mannheim, Germany).
Sections were hybridized with Hdc/Gad67 or Hdc/Vgat RNA
probes at 65°C in hybridization buffer for 16 to 18 h. Slides were
washed in 50% formamide/2.5× SSC (3 × 30 min) and then in
50% formamide/1× SSC (3 × 30 min). Sections were incubated
with blocking solution (5% normal sheep serum in PBS-Tween
0.1%) for 1 h at room temperature. Horseradish peroxidase
conjugated antibodies against DIG (1:500; Roche, cat
11207733910), DNP (1:200; PerkinElmer cat FP1129) or FITC
(1:500; Roche, cat 11426346910) were applied to sections and
incubated overnight at 4°C. Probes were detected sequentially:
first detection with antibody and tyramide signal amplification
(TSA reaction), inactivation of peroxidase with 0.1 M glycine-
HCl buffer (pH 2.0, for 10–15 min), incubation with blocking
solution and second probe detection. TSA reaction (TAMRA and
FAM tyramides) was performed as described (Puttonen, 2017;
Puttonen et al., 2018).
Cell Counting
Hdc-positive cells were detected with Zeiss Axio Imager 2 epi-
fluorescent microscope and the presence of second mRNA
Gad67 or Vgat was assessed. Single or double-positive Hdc
cells were marked and counted with Stereoinvestigator
software (MicroBrightField Inc, Colchester, Vermont, USA).
Representative pictures were taken with Leica TCS SP2 AOBS
confocal microscope equipped with a 488-nm argon laser and a
561-nm diode laser. The emission wavelength was set to 500 to
550 nm for FAM and 600 to 670 nm for TAMRA. Stacks of
images were taken at 0.32-µm intervals and collected by
sequential scanning to reduce the crosstalk between channels.Frontiers in Pharmacology | www.frontiersin.org 3Locomotor Activity Assay
Gabrd WT and KO female (n = 38 and n = 41 for WT and KO)
and male (n = 39 and n = 32 for WT and KO) mice were treated
with saline, ciproxifan 1, 3 or 10 mg/kg (n = 14–22 animals per
group) and placed back to the home cage. Thirty minutes after
treatment mice were placed in the center of the open field
without habituation period. Locomotor activity was tracked in
a testing chamber (43.2 × 43.2 × 30.5 cm) equipped with x and y
infrared 16-beam arrays for horizontal movements and one 16-
beam array for vertical activity (MedAssociates, Georgia,
Vermont, USA) for 30 min. Tracks were analyzed with
Activity monitor software version 6.02 (MedAssociates).
Parameters, such as distance travelled and vertical activity
(vertical counts or number of times that the animal rears and
vertical time or time spent rearing in seconds), were measured.
For testing the effect of pitolisant on locomotion, Gabrd WT
and KO mice (females WT n = 17, KO n = 18; males WT n = 17,
KO n = 13) were treated with saline, pitolisant 5 or 15 mg/kg (n =
8–13 animals per group) and placed back to the home cage.
Thirty minutes after treatment the mice were placed in the center
of an empty plastic cage (40 × 26 × 20 cm) without a habituation
period. Locomotor activity of the animals was monitored with a
video camera and Ethovision XT 10.1 (Noldus Information
Technology, Wageningen, Netherlands) software for 30 min.
Open field tests were performed between 8 and 11 am.
Surgery
Male mice (Gabrd WT n = 9; KO n = 8) were operated under
isoflurane anesthesia (5% and ~2%, induction and maintenance,
respectively). Mice received subcutaneous injection of carprofen (5
mg/kg) and infiltration of lidocaine (approximately 50 µl) at the
incision site before the start of the procedure. The incision site was
disinfected using Betadine (Takeda Oy, Helsinki, Finland) before
exposing of the calvaria. Calvaria was later cleaned from blood, and
exposed skull was dried with hydrogen peroxide (3% v/v in saline).
The mice were implanted with two gold-coated screws (Surtex gold-
plated posts RST-S4, Dentatus, Spanga, Sweden). One recording
electrode was implanted to the frontal cortex and the other one to
the contralateral parietal cortex for the frontoparietal epidural
recording of EEG (Figure 3A). EMG electrodes (PFA-coated
silver wire, cat. 785500; A-M Systems, WA, USA) were implanted
in the neck musculature. To enhance the dental cement adhesion to
the calvaria, the skull bone was coated with superglue and the
electrodes and screws were secured to the scull with dental cement
(Candulor, Wangen, Germany). Buprenorphine (0.1 mg/kg) was
injected i.p. after the operation to minimize postoperative pain.
Mice were left to recover for at least one week before connecting to
the EEG/EMG recording system.Weight and general appearance of
operated mice were monitored.
EEG Recording and Analyses
First, mice were habituated to EEG/EMG recording system
(attached to contra balanced recording cables) at least for two
days. EEG/EMG signals were amplified (gain 10 000) and
sampled at 1000 Hz using Spike2 software (version 8.07,
Cambridge Electronic Devices, Cambridge, UK).May 2020 | Volume 11 | Article 594
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were manually scored for artifacts.
EEG signals were down-sampled to 200 Hz, bandpass filtered
and signals obtained were Hilbert transformed to extract power-
frequency information. Bandpass windows were constructed
with fir1 Matlab function as follows: lower cutoff frequencies
from 1 to 97.6 Hz and higher cutoff frequencies from 2.6 to 99.2
Hz with 1.4-Hz interval.
For further analyses EEG recordings were binned at 4-s
intervals by using median value of the bin. Epochs, which were
marked as artifacts were removed from further analyses.
The analysis was performed in Matlab R2018a (Mathworks)
using a custom-written code (Cohen, 2014).
The data was then used for plotting EEG power spectrum and
further analyses of delta (1–4 Hz), theta (4–8 Hz), alpha (8–12
Hz), sigma (10–15 Hz), beta (12–30 Hz), gamma1 (30–50 Hz)
and gamma2 bands (50–100 Hz). For analyses of different band
frequencies across bands were averaged and normalized to total
power (sum of powers across all bands/per each time point).
Data was further binned at 1-h intervals by averaging values
within the interval.
Next, the mice (Gabrd WT n = 8; KO n = 7) were treated with
either saline or ciproxifan 3 mg/kg and recorded for 4 h. After a
washout period (at least one week) the mice were treated with
either saline or ciproxifan 10 mg/kg (GabrdWT n = 9; KO n = 8).
Finally, after a washout period (at least two weeks) the mice were
pre-treated with irreversible inhibitor of Hdc enzyme, aFMH 50
mg/kg i.p (at 5 pm). and after ~20 h (at 12 pm next day) treated
with ciproxifan 10 mg/kg (Gabrd WT n = 8; KO n = 7) and
recorded for ~ 5 h. aFMH is a long-lasting histamine synthesis
inhibitor, which at the dose 25 mg/kg i.p. blocks Hdc enzyme
activity to nearly 25% and decrease brain histamine to 50% of the
initial levels after 24 h post-injection (Maeyama et al., 1982).
EEG/EMG signals were recorded during the lights-on period
(inactive period for nocturnal mice). EEG recordings were manually
scored for vigilance states (wakefulness, NREM, and REM sleep)
and artifacts. Scoring was performed on 4-s epochs. Wakefulness
was defined as low-amplitude, high-frequency desynchronized EEG
signal accompanied by high EMG activity; NREM sleep was defined
as high-amplitude, low-frequency signal with low EMG signal; REM
sleep was defined as regular low-amplitude, high-frequency signal
with absent EMG signal.
Power-frequency analysis of EEG signals was performed as
described above. Power of frequencies across bands were
averaged and normalized to baseline power (median value
across 24-h baseline recording for each analyzed frequency).
Further binning at 10-min intervals was made by averaging
values within the interval.
Statistical Analyses
Locomotor activity data was analyzed with two-way ANOVA
with Tukey's post hoc tests (“car” R package, (Fox and
Weisberg, 2018)).
EEG/EMG data (vigilance states and band powers) was analyzed
with non-parametric rank-based method, due to violations of
assumptions of parametric statistical methods [“nparLD” R
package, (Noguchi et al., 2012)]. Post hoc analysis results wereFrontiers in Pharmacology | www.frontiersin.org 4corrected with Holm-Bonferroni correction. Detailed statistics for
combination of factors (treatment, genotype, time) are included in
the Supplementary Table 1.
Baseline EEG power spectrum during lights-on and -off times
was analyzed with t-test for each frequency. Wake, NREM, and
REM relative amount and bout duration were analyzed with post
hoc t-tests for each time interval (saline vs ciproxifan 3 or 10 mg/
kg). Significance threshold for t-tests was p < .05.
Data is represented as mean ± SEM. Statistics were done using
R 3.5.0 (R Core Team, 2018).
Significance codes used in the figures:
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤.001 for differences between
the genotypes
# p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001 for differences between
the treatmentsRESULTS
Co-Localization of Gad67 and Vgat With
Hdc mRNA
Double in situ hybridization analyses showed that the majority of
Hdc positive cells also express Gad67 (Figure 1A) and Vgat
mRNA (Figure 1B). On average, 210 ± 27 (for Hdc/Gad67
dFISH) and 232 ± 33 (for Hdc/Vgat dFISH) Hdc-positive cells
were counted per animal (mean ± SEM). Average proportion of
double-positive cells from the total number of counted Hdc cells
were: 99.82 ± 0.12% (n = 5) for Gad67 and 93.43 ± 0.34% (n = 5)
for Vgat (values expressed as mean ± SEM).
Effect of Hrh3 Antagonist/Inverse Agonists
on Open-Field Locomotor Activity
Saline-treated Gabrd KO mice travelled longer distance in the
open field than WT animals. Ciproxifan treatment led to
decreased locomotor activity in both Gabrd WT and KO
groups (treatment effect F(3,134) = 15.65, p = 8.8e-09, Figure
2A), but the dose response was different between the two
genotypes. In Gabrd KO mice all ciproxifan doses decreased
distance traveled compared with saline treatment, while in WT
animals only 10 mg/kg of ciproxi fan significant ly
decreased locomotion.
Ciproxifan treatment decreased the number of vertical counts
(treatment effect F(3,134) = 37.81, p = 2e-16, Figure 2B). In
addition, there was an overall effect of genotype and gender (KO
mice had more vertical counts than WT mice, genotype effect F
(1,134) = 4.16, p = 0.04; males had more vertical counts than
females, sex effect F(1,134) = 4.27, p=.04). Vertical counts were
similarly decreased in Gabrd WT and KO mice by ciproxifan
compared with saline treated mice.
Vertical time was affected by ciproxifan in a similar manner
(treatment effect F(3,134) = 22.69, p = 6.1e-12, Figure 2C) in
both genotypes. There was an overall effect of all ciproxifan
doses, but post hoc analyses with multiple corrections showed no
effect of the lowest ciproxifan dose (WT saline vs ciproxifan 1
mg/kg; KO saline vs ciproxifan 1 mg/kg). Again, there was an
overall effect of genotype and gender (KO mice had increasedMay 2020 | Volume 11 | Article 594
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FIGURE 1 | Co-localization of Hdc mRNA with Gad67 or Vgat mRNA on maximum intensity projection images. (A) A representative image of double fluorescence in
situ hybridization of Hdc and Gad67 in a coronal section of mouse brain on level −2.30 mm from Bregma. Scale bar is 200 µm. (B) A representative image of double
fluorescence in situ hybridization of Hdc and Vgat in a coronal section of mouse brain on level −2.30 mm from Bregma. Scale bar is 100 µm. Small arrows indicate
double-stained neurons, arrowheads denote cells with only one marker.A B
C D
FIGURE 2 | Effect of Hrh3 antagonists/inverse agonists on locomotion during the lights-on period. (A) Distance travelled in the open field after treatment with saline
or different doses of ciproxifan (1, 3 and 10 mg/kg i.p.). (B) Vertical counts (frequency of rearings) in the same open field test. Number of animals is the same as in A.
panel. (C) Vertical time (time spent rearing) in the same open field test. Number of animals is the same as in A. panel. (D) Distance travelled in the open field after
treatment with saline or different doses of pitolisant (5 and 15 mg/kg i.p.). #p ≤ .05, ##p ≤ .01, ###p ≤ .001 for differences between the treatments.Frontiers in Pharmacology | www.frontiersin.org May 2020 | Volume 11 | Article 5945
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(1,134) = 3.85, p = 0.05; and males had increased vertical time
compared with females, sex effect F(1,134) = 47.66, p = 1.8e-10).
Pitolisant treatment decreased locomotor activity similarly to
ciproxifan (treatment effect F(2,53) = 18.89, p = 6.4e-07, Figure
2D). Gabrd KO mice were sensitive to the lowest dose of
pitolisant, 5 mg/kg, while there was no effect in WT mice. A
high dose of pitolisant 15 mg/kg decreased locomotion in both
genotypes compared with saline-treated groups (p = 7.3e-04 and
p = 8.7e-04 for WT and KO, post hoc tests).
Baseline EEG Spectral Power in GABAA d
Subunit KO Mice
Low and high frequencies were enhanced in KOmice, while mid-
range frequencies (5–30 Hz) were suppressed, compared with
WT group (Figures 3B, C). The differences were most
pronounced during inactive (lights-on) period of the animals
(Figure 3B). Delta power was increased in Gabrd KO mice
compared with WT mice (genotype effect c2(1, N = 17), p =Frontiers in Pharmacology | www.frontiersin.org 64.04e-05, Figure 3D), while theta, alpha, sigma, and beta powers
were lower in KO mice (genotype effect c2(1, N = 17), p = 1.18e-
03, p = 1.06e-04, p = 1.59e-07, and p = 2.38e-05, respectively,
Figure 3D). Gamma band powers were similar between the
genotypes, although there were significant genotype–time
interactions (c2(15, N = 17), p = 1.57e-12, and p = 2.64e-15,
respectively, for gamma1 and gamma2 bands, Figure 3D).
Effect of Ciproxifan on Sleep–Wake States
Ciproxifan treatment led to sustained wakefulness and decreased
relative amount of NREM and REM episodes (treatment effect c2
(2, N = 32), p = 7.7e-19, p = 1.2e-22, p = 8.9e-09, Figure 4A).
Both doses 3 and 10 mg/kg of ciproxifan increased the relative
number of wake episodes in Gabrd WT and KO mice compared
with corresponding saline treated groups. In WTmice ciproxifan
increased the number of wake episodes dose-dependently, while
in Gabrd KO mice there was no significant difference between
the two doses of ciproxifan. The relative amount of NREM
episodes was decreased in both genotypes and again a dose-A B
C
D
FIGURE 3 | Baseline EEG properties of Gabrd KO mice. (A) Schematic representation of EEG electrode placement (red dots). (B) EEG power spectrum during
inactive (lights-on) and active (lights-off) periods. The black line above shows significant differences between the genotypes (n = 9 and 8 for WT and KO,
respectively). (C) Representative examples of the power spectrum from 24-h baseline EEG recordings of Gabrd WT and KO mice. Arrows indicate beginning of
lights-off time. Lower panels show power of delta and sigma bands. ZT – zeitgeber time. (D) Normalized power of frequency bands in Gabrd WT and KO mice (n = 9
and 8 for WT and KO, respectively).May 2020 | Volume 11 | Article 594
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was a significant effect of treatment on REM sleep (treatment
effect c2(2, N = 32), p = 8.9e-09). REM sleep suppression after 3
mg/kg ciproxifan did not reach statistical significance in either
genotype. The effect of the higher 10-mg/kg dose of ciproxifan
was highly significant in WT mice, but not in Gabrd KO mice.
Ciproxifan 3 mg/kg induced sustained wakefulness and NREM
sleep suppression in Gabrd KO mice, while Gabrd WT mice
returned to the baseline level faster (Figure 4A, post hoc t-tests).
A similar effect of ciproxifan was found on bout duration. The
wake bout duration was increased (treatment effect c2(2, N = 32),
p = 2e-14, Figure 4B), but NREM and REM bout durations were
decreased after the ciproxifan (treatment effect c2(2, N = 32), p =
8.5e-18, p = 8.8e-09, Figure 4B). The wake bout duration after 3
mg/kg ciproxifan treatment was significantly increased in Gabrd
KO mice, but not in WT mice. The NREM bout duration was
decreased by both doses of ciproxifan in both genotypes. However,
in WT mice the response was dose dependent, while in Gabrd KO
mice there was no difference between the two doses of ciproxifan
used. NREM bout duration was shorter in Gabrd KO mice than in
WT mice after 3 mg/kg ciproxifan treatment. In addition, NREM
bout duration reached the control level later in Gabrd KOmice than
inWT (Figure 4B, post hoc t-tests). The effect of 3 mg/kg ciproxifan
on REM bout duration was not significant in either genotype.
Ciproxifan 10 mg/kg decreased REM bout duration in the WT
group, but not in the Gabrd KO group.
Effect of Ciproxifan on EEG
Spectral Power
Ciproxifan treatment suppressed delta power (treatment effect c2(2,
N = 32), p = 6.4e-06, Figures 5A, B). While the high dose of
ciproxifan reduced delta power in both genotypes, treatment with 3
mg/kg of ciproxifan significantly reduced delta power in Gabrd KO
mice, but not in WT mice. Ciproxifan suppressed theta power
(treatment effect c2(2, N = 32), p = 1.33e-06, Figure 5B). In
addition, there was a significant overall effect of genotype (c2(1,
N = 32), p = 4.52e-02). For theta frequencies, the effect of 3mg/kg of
ciproxifan was opposite to delta waves: 3 mg/kg of ciproxifan
reduced theta power in GabrdWTmice, but not in Gabrd KOmice.
The high 10 mg/kg dose of ciproxifan suppressed alpha power,
while the effect of 3 mg/kg ciproxifan did not reach significance
threshold (Figure 5B). Furthermore, alpha power of Gabrd KO
mice was higher than inWTmice after treatment with the high dose
of ciproxifan (Figures 5A, B). The effect of ciproxifan on sigma
oscillations was similar to alpha waves, sigma power of Gabrd KO
mice was higher than inWTmice after treatment with the high dose
of ciproxifan (Figure 5B). Ciproxifan suppressed beta power
(treatment effect c2(2, N = 32), p = 5e-05, Figure 5B). Post hoc
analyses showed no significant effect after 3mg/kg ciproxifan inWT
and KO. The high dose of ciproxifan suppressed beta power in both
Gabrd WT and Gabrd KO mice.
Although there was an overall effect of ciproxifan treatment
(c2(2, N = 32), p = 8.38e-03, Figure 5B) and ciproxifan
treatment seemed to increase gamma1 power, post hoc analyses
did not reveal any significant effect of ciproxifan doses analyzed
separately in Gabrd WT and Gabrd KO mice. The highest doseFrontiers in Pharmacology | www.frontiersin.org 7of ciproxifan increased gamma2 power in both genotypes, while
the effect of 3 mg/kg ciproxifan did not reach significance
threshold (Figures 5A, B).
Effect of Alpha-FMH Pre-Treatment on
Ciproxifan-Induced Wakefulness
Pre-treatment with aFMH suppressed ciproxifan (10 mg/kg)-
induced sustained wakefulness (treatment effect c2(1, N = 15),
p = 7.16e-19, Figure 6) and promoted NREM and REM sleep
(treatment effects c2(1, N = 15), p = 8.38e-19, p=.03, Figure 6). Post
hoc analyses showed similar effects of aFMH pre-treatment on the
number of wake and NREM sleep episodes in WT and Gabrd KO
mice. aFMH pre-treatment rescued REM sleep in WT mice, but in
KO mice there was no difference between the two treatments.DISCUSSION
Double fluorescence in situ hybridization of Hdc mRNA with
Gad67 or Vgat mRNA showed high co-localization rates, which
further supports the hypothesis of vesicular release of GABA
from histamine/GABA neurons. The reasons for discrepancy
between recently published data (Venner et al., 2019), where
VgatmRNA was found only in a few Hdc immune-positive cells,
and our study are unclear. Methodological differences (double
fluorescence in situ hybridization vs fluorescence in situ
hybridization and immunostaining; in situ hybridization
technique: hybridization temperature, washing stringency) or
regional differences (histaminergic neurons throughout the
anterior-posterior axis vs only the ventral subregion of the
histaminergic neuron population) may play a role.
Interestingly, while optogenetic stimulation of histaminergic
axons in the neocortex and striatum induces direct tonic GABA
current (Yu et al., 2015), no such effect was found upon stimulation
of histaminergic fibers in ventrolateral preoptic nucleus area
(Williams et al., 2014). Given that we found Gad67 and Vgat
mRNA in a majority of histamine/GABA neurons it is possible that
histamine and GABA release is spatially segregated even within one
neuron or release of these neurotransmitters is triggered by different
stimulation parameters.
In the present study, we used mice lacking GABAA d subunits
(Gabrd KO) (Mihalek et al., 1999) and Hrh3 antagonists to
pharmacologically manipulate the release of GABA and
histamine from the histamine/GABA neurons in order to
understand whether the tonic GABAergic inhibition would
limit the excitatory responses to altered histamine/GABA
release. We found that Gabrd KO mice were more sensitive to
the lower doses of ciproxifan (1 mg/kg) and pitolisant (5 mg/kg)
in locomotor activity assay than WT mice. Also, EEG/EMG
experiments revealed higher sensitivity of Gabrd KO mice to the
lower dose of ciproxifan (3 mg/kg), showing prolonged sustained
wakefulness compared withWTmice, in which this dose only led
to a short-lasting effect.
Hrh3 antagonist treatment leads to increased wakefulness,
but decreased locomotion and rearing as seen by us here and
reported also earlier [(Ligneau et al., 1998; Fox et al., 2003;May 2020 | Volume 11 | Article 594
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FIGURE 4 | Effect of ciproxifan on vigilance states during the lights-on period. (A) Relative amount of Wake, NREM, and REM episodes in Gabrd WT and KO mice
during the next 4 h after treatment with saline, ciproxifan 3 or 10 mg/kg. (B) Wake, NREM, and REM bout duration in Gabrd WT and KO mice treated with saline,
ciproxifan 3 or 10 mg/kg (n = 7, 5, and 5 for WT saline, cip3, and cip10, respectively; n = 6, 4, and 5 for KO saline, cip3, and cip10, respectively). Red and pink bars
above show significant differences between the saline and treatment groups for each time interval (red for ciproxifan 3 mg/kg and pink for 10 mg/kg). ***p ≤ .001 for
differences between the genotypes. ##p ≤ .01, ###p ≤ .001 for differences between the treatments.
Abdurakhmanova et al. GABA in Brain Histamine NeuronsLigneau et al., 2007; Vanhanen et al., 2015); but see also (Mohsen
et al., 2014)]. It is unclear what the specific mechanism of
locomotor regulation by histamine and Hrh3 ligands are, since
activation of histamine/GABA neurons with the chemogenetic
DREADD (Designer Receptors Exclusively Activated by
Designer Drugs) approach leads to increased locomotion (Yu
et al., 2015). The decrease in locomotion is unlikely due to direct
sedation via extrasynaptic inhibition by GABAA d receptors,
since the Gabrd KO mice were more sensitive to the effect. Hrh3
receptors act not only as autoreceptors, providing negative
feedback to histamine/GABA neurons, but also as pre- and
post-synaptic heteroreceptors on other neuronal populations
(Panula et al., 2015; Nieto-Alamilla et al., 2016). For example,
Hrh3 presynaptic receptors regulate release of glutamate, GABA,
noradrenaline, serotonin, and dopamine (Arrang et al., 1983;
Schlicker et al., 1993; Threlfell et al., 2004; Aquino-Miranda et al.,
2012; Takei et al., 2017). Therefore, it is possible that the decrease
in locomotion was mediated by Hrh3 located on other neurons.
There was a clear difference in baseline EEG properties
between Gabrd WT and KO mice, especially during the lights-
on (inactive) period. In Gabrd KO mice delta (1–4 Hz) and
gamma2 (50–100 Hz) band powers were more prominent
compared with those in the WT mice. A previous study found
a similar increase of baseline NREM delta power in Gabrd KO
mice (Mesbah-Oskui et al., 2014). The authors speculated that
such differences would indicate more hyperpolarized resting
membrane potential in thalamocortical neurons of Gabrd KO
mice due to compensational changes. In the mouse cerebellar
granule cells, abolition of GABAA d receptor-mediated inhibition
promotes expression of potassium leak channel TASK-1,
providing compensatory baseline hyperpolarization (Brickley
et al., 2001), but similar changes in forebrain neurons in the
Gabrd KO mice have not been studied.
The waking effect of 3 mg/kg ciproxifan was more pronounced
in Gabrd KO mice. Relative amount and bout duration of NREM
sleep were suppressed by treatment in a greater extent in Gabrd
KO mice. The effect of ciproxifan on power of frequency bands
was also different between GabrdWT and KOmice. For example,
delta band of Gabrd KO mice, which was more pronounced in
KO mice at the baseline, was significantly suppressed by
ciproxifan 3 mg/kg treatment. In contrast, theta band, which
had lower baseline power in Gabrd KO mice, was suppressed in
WT, but not in Gabrd KOmice. Interestingly, gaboxadol, GABAA
d receptor-preferring hypnotic agonist, has been shown to induce
strong EEG delta waves in WT mice, but not in Gabrd KO mice
(Winsky-Sommerer et al., 2007), indicating that pharmacological
enhancement of extrasynaptic inhibition potentiates the delta
EEG frequencies via GABAA d receptors. Therefore,
compensatory changes in the Gabrd KO mice might explain
their higher baseline delta band activity. The greater suppressionFrontiers in Pharmacology | www.frontiersin.org 9of delta band EEG in Gabrd KO mice by Hrh3 antagonists can
then be explained by increased histamine release, in the absence of
counteracting extrasynaptic GABAA inhibition.
Effects of the higher dose of ciproxifan 10 mg/kg were more
evident in WT mice than in Gabrd KO mice. REM sleep was
significantly suppressed by the treatment in WT mice, but not in
Gabrd KO mice. Alpha and sigma bands were more suppressed
by the treatment in WT mice than in KO mice.
The wake-promoting effect of the Hrh3 antagonist ciproxifan,
as analyzed via EEG recordings, was attenuated by aFMH
treatment, leading to depletion of histamine, with both mouse
lines showing similar responses, suggesting that histamine is
responsible for the observed differences between the genotypes.
The rodent EEG signal mainly reflects the activity of the
cerebral cortex and hippocampus, due to the location of
electrodes, cytoarchitecture and synchronized neuronal activity
of these brain structures, and the thalamus, which tightly regulates
cortical activity (Buzsáki et al., 2012). It has been shown that
GABA from the histamine/GABA neurons induces inhibitory
tonic currents in cortical pyramidal neurons (Yu et al., 2015),
which strongly contribute to generation of synchronized activity
detected by EEG. Sparse histamine-immunoreactive fibers are
found in the cortex and hippocampus (Panula et al., 1989)
suggesting paracrine-like volume transmission of released
histamine in these brain areas. GABAA d receptors are also
present in the cortex and hippocampus, although their density
is highest in the thalamus and cerebellum (Wisden et al., 1992).
The hypervigilant EEG phenotype in Gabrd KO mice after
ciproxifan treatment is then most probably due to histamine-
induced over-excitation and lack of GABAA d receptor-mediated
inhibition in the cortex, hippocampus, and thalamus. The cortical
pyramidal neurons might be the main contributor in the observed
effect as they are the closest to the recording electrodes. Neuronal
type affected by GABA released from histamine/GABA neurons
remains yet to be established in other brain regions.
It should be noted that in addition to GABAA d subunit-
containing receptors there are also other GABA receptors
providing tonic extrasynaptic inhibition including GABAA
receptors composed of a5bg2 subunits (Brickley and Mody, 2012)
and GABAB receptors. GABAB receptors are not only able to induce
extrasynaptic currents (Scanziani, 2000), but they also enhance tonic
GABAA currents (Connelly et al., 2013). Therefore, the magnitude
of the wake-promoting effect of Hrh3 inverse agonists might be
even larger in the absence of also the other forms of high-affinity
extrasynaptic GABAA receptors (Chandra et al., 2010).
We should point out technical limitations of the study that
require careful interpretation of the results. First, there are
compensatory changes due to global knock-out of GABAA d
subunit gene. Alterations in assembly of other GABAA receptor
subunits have been found in Gabrd KO mice (Korpi et al., 2002).May 2020 | Volume 11 | Article 594
and KO mice after treatment with saline or ciproxifan 10 mg/kg. Lower panels show










































FIGURE 5 | Effect of ciproxifan on EEG power spectrum. (A) Example power spectrum from EEG recordings of Gabrd WT
power of delta, alpha, and gamma2 bands in Gabrd WT and KO mice after treatment with ciproxifan 10 mg/kg. (B) Normali
or 10 mg/kg (n = 7, 5, and 5 for WT saline, cip3, and cip10, respectively; n = 6, 4, and 5 for KO saline, cip3, and cip10, res
Abdurakhmanova et al. GABA in Brain Histamine NeuronsSecondly, we used a pharmacological approach to block Hrh3
autoreceptors and induce release of neurotransmitters from
histamine/GABA neurons. The treatment of mice with the
Hrh3 antagonist/inverse agonist ciproxifan indeed led to
sustained wakefulness, which was blocked with aFMH pre-
treatment, suggesting that histamine is essential for wakefulness.
Nevertheless, Hrh3 receptors act not only as autoreceptors,
providing negative feedback to histamine/GABA neurons, but
also as pre- and post-synaptic receptors on other neuronal
populations (Panula et al., 2015; Nieto-Alamilla et al., 2016).
Non-pharmacological approaches should also be examined, since
unlike the Hrh3 antagonist treatments, selective activation of
histaminergic neurons leads to hyperlocomotion (Yu et al., 2015).Frontiers in Pharmacology | www.frontiersin.org 11To summarize, we showed increased sensitivity of Gabrd KO
mice to the locomotion suppression effects of the Hrh3
antagonists/inverse agonists ciproxifan and pitolisant.
Treatment of Gabrd KO mice with the lower dose of
ciproxifan led to sustained wakefulness and inhibition of low
frequency delta oscillations in a greater extent than that of WT
mice, consistent with our initial hypothesis. Treatment with the
higher dose of ciproxifan led to more pronounced effects in WT
than in KOmice, reflecting, possibly, a ceiling effect of a ligand or
compensational changes in KO mice. Another possibility is that
the different isoforms of Hrh3 (Drutel et al., 2001; Panula et al.,
2015) on different domains of the circuits involved are recruited
at different ligand concentrations.FIGURE 6 | Effect of aFMH pre-treatment on ciproxifan-induced sustained wakefulness. Relative amount of Wake, NREM, and REM episodes in Gabrd WT and KO
mice pre-treated with either saline or aFMH and 20 h later treated with ciproxifan 10 mg/kg (n = 4 for WT saline+ciproxifan and aFMH+ ciproxifan; n = 3 and n = 4
for KO saline+ciproxifan and aFMH+ ciproxifan, respectively). #p ≤ .05, ###p ≤ .001 for differences between the treatments.May 2020 | Volume 11 | Article 594
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